Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial

Christine R. Jenkins, Fu-Qiang Wen, Allison Martin, Peter J. Barnes, Bartolome Celli, Nan-Shan Zhong, Jin-Ping Zheng, Anish Scaria, Gian-Luca Di Tanna, Thomas Bradbury, Norbert Berend on behalf of the TASCS study investigators
European Respiratory Journal 2021 57: 2003338; DOI: 10.1183/13993003.03338-2020
Christine R. Jenkins
1The George Institute for Global Health, Sydney, Australia
2Faculty of Medicine, UNSW Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christine R. Jenkins
  • For correspondence: christine.jenkins@sydney.edu.au
Fu-Qiang Wen
3West China Hospital, Sichuan University, Chengdu, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allison Martin
1The George Institute for Global Health, Sydney, Australia
2Faculty of Medicine, UNSW Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Barnes
4National Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bartolome Celli
5Pulmonary and Critical Care Division, Brigham and Women's Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bartolome Celli
Nan-Shan Zhong
6State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jin-Ping Zheng
6State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anish Scaria
1The George Institute for Global Health, Sydney, Australia
2Faculty of Medicine, UNSW Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gian-Luca Di Tanna
1The George Institute for Global Health, Sydney, Australia
2Faculty of Medicine, UNSW Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gian-Luca Di Tanna
Thomas Bradbury
1The George Institute for Global Health, Sydney, Australia
2Faculty of Medicine, UNSW Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norbert Berend
1The George Institute for Global Health, Sydney, Australia
2Faculty of Medicine, UNSW Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background The highest burden of chronic obstructive pulmonary disease (COPD) occurs in low- and middle-income countries. Low-cost oral medications, if effective, could enable affordable, accessible COPD treatment.

Methods In this randomised, three-arm, double-blind, double-dummy, placebo-controlled study conducted in 37 centres in China, symptomatic patients with moderate to very severe COPD were randomised 1:1:1 to placebo twice daily plus placebo once daily, low-dose theophylline 100 mg twice daily plus placebo once daily or low-dose theophylline 100 mg twice daily plus low-dose oral prednisone 5 mg once daily for 48 weeks. The primary end-point was annualised exacerbation rate.

Results 1670 subjects were randomised and 1242 completed the study (1142 with acceptable data at week 48). Subjects (75.7% male) had a mean age of 64.4 years, with mean±sd baseline post-bronchodilator forced expiratory volume in 1 s (FEV1) 1.1±0.4 L (42.2% predicted) and St George's Respiratory Questionnaire (SGRQ) score 45.8±20.1. There were negligible differences between annualised exacerbation rates across the three treatments: 0.89 (95% CI 0.78–1.02) on theophylline plus prednisone, 0.86 (95% CI 0.75–0.99) on theophylline plus placebo and 1.00 (95% CI 0.87–1.14) on placebo. The rate ratio for theophylline plus prednisone versus pooled theophylline plus placebo and placebo was 0.96 (95% CI 0.83–1.12), for theophylline plus placebo versus placebo was 0.87 (95% CI 0.73–1.03; p=0.101) and for theophylline plus prednisone versus placebo was 0.90 (95% CI 0.76–1.06; p=0.201). Secondary outcomes of hospitalisations, FEV1, SGRQ and COPD Assessment Test score showed no statistically significant difference between treatment arms. Serious adverse events other than exacerbations were <2% and did not differ between treatment arms.

Conclusions Low-dose theophylline alone or in combination with prednisone did not reduce exacerbation rates or clinically important secondary end-points compared with placebo.

Abstract

This large, rigorously conducted RCT showed that the combination of low-dose theophylline and prednisone did not affect exacerbation rate in patients with moderate to severe COPD in China https://bit.ly/2KSQ2BK

Footnotes

  • This article has an editorial commentary: https://doi.org/10.1183/13993003.04564-2020

  • This article has supplementary material available from erj.ersjournals.com

  • This study is registered at ClinicalTrials.gov with identifier number NCT02261727. Individual de-identified participant data are available on application to the corresponding author. The protocol and statistical analysis plan are available on the Centre for Open Science website: https://osf.io/39qkm

  • Author contributions: C.R. Jenkins, N. Berend, P.J. Barnes and B. Celli contributed to the study concept and design, data interpretation, and final approval of the manuscript. A. Martin contributed to implementation of the study, data collection, cleaning, interpretation and final approval of the manuscript. A. Scaria, G-L. Di Tanna and T. Bradbury contributed to statistical analysis and interpretation, and final approval of the manuscript. F-Q. Wen, N-S. Zhong, J-P. Zheng and A. Martin contributed to the study execution, data interpretation, review and final approval of the manuscript. C.R. Jenkins wrote the primary manuscript, and all authors revised and contributed to its final review. C.R. Jenkins had full access to all the data in the study and had final responsibility for the decision to submit for publication.

  • Conflict of interest: C.R. Jenkins reports personal fees from Boehringer Ingelheim and Chiesi, grants, personal fees and nonfinancial support from GlaxoSmithKline, personal fees and nonfinancial support from AstraZeneca, Novartis and Sanofi Genzyme, outside the submitted work.

  • Conflict of interest: F-Q. Wen has nothing to disclose.

  • Conflict of interest: A. Martin has nothing to disclose.

  • Conflict of interest: P.J. Barnes reports grants and personal fees for consultancy and advisory board work from AstraZeneca, grants and personal fees for advisory board work and lectures from Boehringer Ingelheim, personal fees for advisory board work and lectures from Novartis and Teva, personal fees for advisory board work from Pieris and Epi-Endo, outside the submitted work.

  • Conflict of interest: B. Celli reports grants and research facilities from AstraZeneca, personal fees for consultancy and scientific committee work from GlaxoSmithKline, personal fees for consultancy from Boehringer Ingelheim, Sanofi-Aventis, Menarini, Chiesi and Pulmonx, outside the submitted work.

  • Conflict of interest: N-S. Zhong has nothing to disclose.

  • Conflict of interest: J-P. Zheng has nothing to disclose.

  • Conflict of interest: A. Scaria has nothing to disclose.

  • Conflict of interest: G-L. Di Tanna is a former employee of Amgen.

  • Conflict of interest: T. Bradbury reports receiving a top-up scholarship funded by GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: N. Berend reports grants from the National Health and Medical Research Council, Australia, State Key Laboratory of Respiratory Disease and Guangzhou Institute of Respiratory Disease China, and West China Hospital, Chengdu, China, during the conduct of the study; and a salary from GlaxoSmithKline, outside the submitted work.

  • Support statement: This work was supported by the National Health and Medical Research Council, Australia; State Key Laboratory of Respiratory Diseases and Guangzhou Institute of Respiratory Diseases, Guangzhou, China; and West China Hospital, Chengdu, China. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received September 1, 2020.
  • Accepted November 21, 2020.
  • Copyright ©ERS 2021. For reproduction rights and permissions contact permissions{at}ersnet.org
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 6 Table of Contents
European Respiratory Journal: 57 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial
Christine R. Jenkins, Fu-Qiang Wen, Allison Martin, Peter J. Barnes, Bartolome Celli, Nan-Shan Zhong, Jin-Ping Zheng, Anish Scaria, Gian-Luca Di Tanna, Thomas Bradbury, Norbert Berend
European Respiratory Journal Jun 2021, 57 (6) 2003338; DOI: 10.1183/13993003.03338-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial
Christine R. Jenkins, Fu-Qiang Wen, Allison Martin, Peter J. Barnes, Bartolome Celli, Nan-Shan Zhong, Jin-Ping Zheng, Anish Scaria, Gian-Luca Di Tanna, Thomas Bradbury, Norbert Berend
European Respiratory Journal Jun 2021, 57 (6) 2003338; DOI: 10.1183/13993003.03338-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Identifying early PAH biomarkers in systemic sclerosis
  • Viable virus aerosol propagation by PAP circuit leak
  • Ambulatory management of secondary spontaneous pneumothorax
Show more Original Articles

COPD

  • Use of singing for lung health in COPD
  • Response to exercise training and withdrawal in COPD
  • A phase 2a crossover trial in COPD of the bronchodilator navafenterol
Show more COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society